Skip to main content

Table 2 Details of the chemotherapy regimens and number of cycles between patients with and without LS

From: Incidence and predictors of Lhermitte’s sign among patients receiving mediastinal radiation for lymphoma

Chemotherapy

No LS

LS

2–4 ABVD/AVD

24

9

>4 ABVD/AVD

22

11

≥6 R-CHOP

2

1

≥6 R-EPOCH

6

2

≥6 HyperCVAD

1

0

Salvage

20

7

  1. ABVD/AVD: Doxorubicin, Bleomycin, Vinblastine, Dacarbazine
  2. R-CHOP: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
  3. R-EPOCH: Rituximab, Etoposide, Prednisolone, Vincristin, Cyclophosphamide, Doxorubicin
  4. HyperCVAD: Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone, Methotrexate, Cytarabine
  5. Salvage: Multiple lines of chemotherapy +/− Stem cell transplantation